Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 3:00 p.m. PT in San Francisco.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.enanta.com, and a replay will be archived for at least 30 days following the presentation.
Summary not available.
Enanta Pharmaceuticals (NASDAQ:ENTA) said company management will participate in investor conferences in November and December 2025. Jefferies London Global Healthcare Conference fireside chat is scheduled for Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET. Evercore Healthcare Conference fireside chat is scheduled for Wednesday, December 3, 2025 at 8:20 a.m. ET.
A live webcast of each event will be available on the company’s Investors page under Events and Presentations at www.enanta.com, with replays archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) presented new clinical data for two oral RSV antivirals at IDWeek 2025: zelicapavir (EDP-938), an N‑protein inhibitor, and EDP‑323, an L‑protein inhibitor. A post hoc analysis of a Phase 2 pediatric trial (n=96) found zelicapavir shortened median time to complete resolution of RSV symptoms to 6.99 days vs 8.60 days for placebo and sustained resolution to 6.99 vs 10.68 days. Human viral challenge Phase 2a data for EDP‑323 showed rapid symptom and viral load reductions (total symptom AUC reductions: 73% 200mg, 61% 600mg, pooled 67%; viral load AUC reductions: 87% 200mg, 85% 600mg) and strong post‑exposure prophylaxis (PEP) effect: 0% infections in 45 treated vs 26% (6/23) placebo, p<0.001. Both programs reported similar adverse event rates versus placebo and no treatment‑related discontinuations.
Enanta (NASDAQ:ENTA) will present clinical data for two oral RSV candidates, zelicapavir (EDP-938) and EDP-323, at IDWeek 2025 held October 19–22, 2025 in Atlanta and virtually. Zelicapavir has a rapid-fire talk and a poster on October 20 reporting shortened RSV symptom duration in a randomized, double-blind, placebo-controlled pediatric trial (children 28 days–36 months). EDP-323 has an oral presentation on October 20 plus a poster on October 22 reporting rapid reductions in RSV symptoms and viral load after human viral challenge. Posters will be posted on the conference platform and the company website.
Enanta (NASDAQ:ENTA) announced on October 2, 2025 the closing of an upsized underwritten public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares sold pursuant to full exercise of the underwriters’ option. Gross proceeds to Enanta were $74.75 million before underwriting discounts, commissions and offering expenses. All shares were offered by Enanta. Net proceeds will be used, together with existing cash and investments, to fund clinical trials, research and development, working capital and general corporate purposes. J.P. Morgan, Jefferies and Evercore ISI acted as joint book‑running managers. The offering was made under a Form S‑3 shelf registration effective February 8, 2024.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced the pricing of an upsized public offering of 6.5 million shares of common stock at $10.00 per share. The offering is expected to generate gross proceeds of $65.0 million before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price. J.P. Morgan, Jefferies, and Evercore ISI are serving as joint book-running managers. The offering, made under a shelf registration statement, is expected to close on October 2, 2025.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company, has announced a proposed public offering of common stock worth $50.0 million. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million of shares at the public offering price, less underwriting discounts and commissions.
The offering will be managed jointly by J.P. Morgan, Jefferies, and Evercore ISI as book-running managers. The offering is being made through a shelf registration statement on Form S-3 that became effective on February 8, 2024. The completion of the offering is subject to market and other conditions.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline results from its Phase 2b RSVHR study of zelicapavir, a novel N-protein inhibitor for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution for patients with COPD, CHF, or age ≥75 (HR3 population).
Key findings include a lower hospitalization rate in the zelicapavir group (1.7%) versus placebo (5.0%), and a 4-5 day faster median time to undetectable viral load. The drug showed statistically significant improvement in Patient Global Impression of Severity scores and demonstrated a favorable safety profile. The study enrolled 186 subjects, with 121 receiving zelicapavir and 65 receiving placebo.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, September 29 at 8:30 a.m. ET. The biotechnology company will present topline results from its Phase 2b RSVHR study evaluating zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults.
The live webcast will be accessible through the investors section of Enanta's website under "Events & Presentations". Participants joining by phone are encouraged to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on the company's website for approximately 30 days after the event.